Lantern Pharma is trading at $0.68 (+6.19%), with broader biotech-sector strength the likeliest available explanation. - Biotech ETF XBI rose 2.18% during the regular session, alongside positive clinical-trial and regulatory news across the industry. - No new company-specific announcement was identified for October 28; Lantern Pharma’s latest listed company release is dated October 8. No direct link to the share move was reported. - Volume or unusual trading activity was not provided.